Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Acute Bronchitis.

Acute Bronchitis Clinical Trial

— AB4T  

Official title:

Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Uncomplicated Acute Bronchitis.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03738917
• Other study ID #: IJG-AB4T-2018
• Status: Completed
• Phase: Phase 4
• Start date: February 1, 2019
• Est. completion date: December 31, 2021

Study information

• Verified date: August 2021
• Source: Jordi Gol i Gurina Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study, which is aimed at comparing the effectiveness of 3 symptomatic therapies (dextromethorphan, ipratropium and honey) associated with usual care and the usual care in adults with acute bronchitis, is a multicentre, pragmatic, parallel group, open randomised trial. Patients aged 18 or over with uncomplicated acute bronchitis, with cough <3 weeks as the main symptom, scoring ≥ 4 in either daytime or nocturnal cough on a 7-point Likert scale, will be randomised to one of the 4 groups. Sample: 668 patients. The primary outcome will be the number of days with moderate-severe cough.

Description:

Despite the frequent use of therapies in acute bronchitis, encouraged by the over-the-counter availability in pharmacies, the evidence of their benefit is scarce, since only a few clinical trials have been published, with low sample sizes, poor methodological quality and mainly in children. The objective of this study is to compare the effectiveness of 3 symptomatic therapies (dextromethorphan, ipratropium and honey) associated with usual care and the usual care in adults with acute bronchitis. This will be a multicentre, pragmatic, parallel group, open randomised trial. Patients aged 18 or over with uncomplicated acute bronchitis, with cough for less than three weeks as the main symptom, scoring ≥ 4 in either daytime or nocturnal cough on a 7-point Likert scale, will be randomised to one of the following four groups: usual care, usual care + dextromethorphan 30 mg t.i.d., usual care + ipratropium bromide inhaler 20 µg 2 puffs t.i.d, or usual care + 30 mg (a spoonful) of honey t.i.d., all taken for up to 14 days. The exclusion criteria will be: pneumonia, criteria for hospital admission, pregnancy or lactation, concomitant pulmonary disease, associated significant comorbidity, allergy, intolerance or contraindication to any of the study drugs, admitted to a long-term residence, or inability to give informed consent. Sample: 668 patients. The primary outcome will be the number of days with moderate-severe cough in the intention-to-treat (ITT) population, i.e., the number of days from the randomisation visit until the last day the patient scores three or more in either daytime or nocturnal cough in the symptom diary. All patients will be given a symptom diary to be self-administered while symptoms are present. A second visit will be scheduled at day 2-3 for assessing evolution, with two more visits at days 15 and 29 for clinical assessment, evaluation of adverse effects, re-attendance and complications. Patients still with symptoms at day 29 will be called six weeks after the baseline visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 668
• Est. completion date: December 31, 2021
• Est. primary completion date: November 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• age 18 years or older, and

• symptoms of acute bronchitis with cough starting within 3 weeks before study inclusion, and

• patients who score = 4 in either the daytime and/or nocturnal cough on a 7-point Likert scale, and

• patients who consent to participate.

Exclusion Criteria:

• suspected pneumonia; if the professional suspects pneumonia, a chest X-ray will be recommended and the patient will be randomized if this diagnosis is discarded; or

• criteria for hospital admission (impaired consciousness, respiratory rate > 30 breaths/minute, pulse > 125 beats/minute, systolic blood pressure <90 mm Hg or diastolic blood pressure <60 mm Hg, temperature > 104°F or oxygen saturation <92%)

• pregnancy or breast feeding

• baseline respiratory disease such as chronic obstructive pulmonary disease, asthma, tuberculosis or bronchiectasis

• associated significant comorbidity, such as moderate-severe heart failure, dementia, acute myocardial infarction/recent cerebral vascular accident (< 3 months), severe liver failure, severe renal failure

• immunosuppression, such as chronic infection by HIV, transplanted, neutropenic, or patients receiving immunosuppressive treatment

• active neoplasm

• terminal illness

• history of intolerance or allergy to any of the study treatments

• patients in whom, in the opinion of the investigator, treatment with dextromethorphan, ipratropium bromide or honey is contraindicated

• patients living in long-term institutions

• difficulty in conducting scheduled follow-up visits

Related Conditions & MeSH terms

• Acute Bronchitis
• Acute Disease
• Bronchitis

Intervention

Drug:
• Dextromethorphan 15 milligrams
This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.
• Ipratropium Bromide 20Micrograms Inhaler
This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.

Dietary Supplement:
• Honey 30 g (full tablespoon)
This study product will be provided free to the participants by the sponsor.

Other:
• Usual clinical practice
Clinicians will not be allowed to prescribe antitussives, including codeine, anticholinergic inhalers and they will not be allowed to recommend the use of honey.

Locations

Country	Name	City	State
Spain	Martí i Julià Health Center	Badalona	Catalonia
Spain	Nova Lloreda Health Center	Badalona	Catalonia
Spain	Balaguer Health Center	Balaguer	Catalonia
Spain	CAP Passeig Maragall (EAP Camp de l'Arpa)	Barcelona	Catalonia
Spain	La Marina Health Center	Barcelona	Catalonia
Spain	Via Roma Health Centre	Barcelona	Catalonia
Spain	Cornellà - La Gavarra Health Center	Cornellà De Llobregat	Catalonia
Spain	Pineda de Mar Health Center	Pineda De Mar	Catalonia
Spain	Ca n'OriacHealth Center	Sabadell	Catalonia
Spain	Molí Nou Health Center	Sant Boi De Llobregat	Catalonia
Spain	Singuerlin Health Center	Santa Coloma De Gramenet	Catalonia
Spain	CAP Jaume I	Tarragona	Catalonia

Sponsors (2)

Lead Sponsor	Collaborator
Jordi Gol i Gurina Foundation	Spanish Clinical Research Network - SCReN

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Duration of moderate-severe cough in days in the four arms.	Number of days until the last day the patient scores 3 in either daytime cough or nocturnal cough in the symptom diary. Each symptom will be scored by the patient on a 7-point Likert scale, which has been used in previous studies (0=not affected; 1=very little problem; 2=slight problem; 3=moderately bad; 4=bad; 5=very bad; 6=as bad as it could be).	Day 29.
Secondary	Duration of cough in days in the four arms.	Number of days until the last day the patient scores 2 in either daytime cough or nocturnal cough in the symptom diary. Each symptom will be scored by the patient on a 7-point Likert scale, which has been used in previous studies (0=not affected; 1=very little problem; 2=slight problem; 3=moderately bad; 4=bad; 5=very bad; 6=as bad as it could be).	Days 15 and 29. If the patient continues to score 2 or more at day 29 will be called at day 43.
Secondary	Duration of moderate-severe daytime cough in days in the four arms.	Number of days until the last day the patient scores 3 in daytime cough in the symptom diary. This symptom will be scored by the patient on a 7-point Likert scale, which has been used in previous studies (0=not affected; 1=very little problem; 2=slight problem; 3=moderately bad; 4=bad; 5=very bad; 6=as bad as it could be).	Days 15 and 29. If the patient continues to score 3 or more at day 29 will be called at day 43.
Secondary	Duration of moderate-severe nocturnal cough in days in the four arms.	Number of days until the last day the patient scores 3 in nocturnal cough in the symptom diary. This symptom will be scored by the patient on a 7-point Likert scale, which has been used in previous studies (0=not affected; 1=very little problem; 2=slight problem; 3=moderately bad; 4=bad; 5=very bad; 6=as bad as it could be).	Days 15 and 29. If the patient continues to score 3 or more at day 29 will be called at day 43.
Secondary	Duration of moderate-severe symptoms in days in the four arms.	Number of days until the last day the patient scores 3 in any of the symptoms in the symptom diary. Each symptom will be scored by the patient on a 7-point Likert scale, which has been used in previous studies (0=not affected; 1=very little problem; 2=slight problem; 3=moderately bad; 4=bad; 5=very bad; 6=as bad as it could be).	Days 15 and 29. If the patient continues to score 3 or more at day 29 will be called at day 43.
Secondary	Duration of severe symptoms in days in the four arms.	Number of days until the last day the patient scores 5 in any of the symptoms in the symptom diary. Each symptom will be scored by the patient on a 7-point Likert scale, which has been used in previous studies (0=not affected; 1=very little problem; 2=slight problem; 3=moderately bad; 4=bad; 5=very bad; 6=as bad as it could be).	Days 15 and 29.
Secondary	Duration of symptoms in days in the four arms.	Number of days until the last day the patient scores 2 in any of the symptoms in the symptom diary. Each symptom will be scored by the patient on a 7-point Likert scale, which has been used in previous studies (0=not affected; 1=very little problem; 2=slight problem; 3=moderately bad; 4=bad; 5=very bad; 6=as bad as it could be).	Days 15 and 29. If the patient continues to score 2 or more at day 29 will be called at day 43.
Secondary	Duration of moderate-severe cough in days according to the basal degree of bronchial hyper-reactiveness in the four arms.	Number of days until the last day the patient scores 3 in either daytime cough or nocturnal cough in the symptom diary. Each symptom will be scored by the patient on a 7-point Likert scale, which has been used in previous studies (0=not affected; 1=very little problem; 2=slight problem; 3=moderately bad; 4=bad; 5=very bad; 6=as bad as it could be). Bronchial hyper-responsiveness will be determined with three peak-flow measurements at day 1 and the highest of three peak flow measurements will be collected.	The peak-flow will be determined at day 1.
Secondary	Percentage of antibiotics and different symptomatic treatments used in the four arms.	This information will be collected every day by the patients themselves.	Days 2-4, 15 and 29.
Secondary	Number of days of absence from work in the four arms.	Electronic records and sick leave certifications.	Day 15.
Secondary	Patients re-attendance for symptoms related to the episode of acute bronchitis within the first 42 days.	The number of re-attendances to any doctor regarding the episode of acute bronchitis will be collected from the electronic records.	Day 29 and phone call at day 43.
Secondary	Number of complications related to the episode of acute bronchitis within the first 28-42 days.	The number of complications will be collected through electronic records and hospital certifications.	Day 29-43.
Secondary	Patient satisfaction in the four arms.	Patient satisfaction will be collected in the same symptom diaries by the patients themselves by means of questions included in the symptom diary.	Day 15 or 29.
Secondary	Number of adverse events in the four arms.	The number of adverse events will be collected by the participating doctor by means of questions.	Days 2-4, 15 and 29.